CPT® Code 90623

Official Description

Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y- tetanus toxoid carrier, and Men B-FHbp, for intramuscular use

Common Language Description

The CPT® Code 90623 refers to the meningococcal pentavalent vaccine, which is designed to provide active, long-term immunity against meningococcal disease. This vaccine works by exposing the recipient's immune system to altered versions of specific pathogens, prompting the immune system to produce its own antibodies. This process enables the body to "remember" how to generate these antibodies upon future exposure to the same antigens. Meningococcal disease, although rare, poses a serious health risk as it can lead to infections of the brain, spinal cord, and bloodstream. Particularly concerning is the MenB strain, which can escalate rapidly and become fatal within a mere 24 hours, primarily affecting adolescents and young adults. The vaccine comprises two sterile components: the pentavalent MenACWY vaccine, which includes equal amounts of polysaccharides conjugated to a tetanus toxoid carrier, and the MenB component, which contains two recombinant lipidated FHbp variants. The MenACWY component is lyophilized for storage and is reconstituted with the MenB component prior to administration. It is important to note that this code specifically reports the vaccine product itself and does not encompass the percutaneous administration of the vaccine.

1. Indications

The meningococcal pentavalent vaccine (CPT® Code 90623) is indicated for the prevention of meningococcal disease caused by the serogroups A, C, W, Y, and B. This vaccine is particularly recommended for specific populations at higher risk, including:

Adolescents and Young Adults: This group is at an increased risk for meningococcal disease, especially during outbreaks or in communal living settings such as college dormitories.
Individuals with Certain Medical Conditions: Those with compromised immune systems or specific medical conditions that increase susceptibility to meningococcal infections may also be advised to receive this vaccine.
Travelers: Individuals traveling to areas where meningococcal disease is endemic or during outbreaks may require vaccination for protection.

2. Procedure

The administration of the meningococcal pentavalent vaccine involves several key procedural steps:

Preparation of the Vaccine: The MenACWY component of the vaccine is freeze-dried and must be reconstituted with the MenB component before administration. This step ensures that the vaccine is in a suitable form for injection.
Site Selection: The vaccine is administered via intramuscular injection, typically in the deltoid muscle of the upper arm for adolescents and adults, or in the anterolateral thigh for infants and young children.
Injection Technique: The healthcare provider will clean the injection site with an antiseptic wipe, allow it to dry, and then use a sterile syringe and needle to inject the vaccine. Proper technique is essential to minimize discomfort and ensure effective delivery of the vaccine.
Post-Injection Monitoring: After administration, the recipient should be monitored for a short period to observe for any immediate adverse reactions, although serious side effects are rare.

3. Post-Procedure

Following the administration of the meningococcal pentavalent vaccine, recipients may experience mild side effects such as soreness at the injection site, low-grade fever, or fatigue. These symptoms typically resolve within a few days. It is important for recipients to be informed about potential side effects and to seek medical attention if they experience any severe or unusual reactions. Additionally, individuals should be advised to keep a record of their vaccination status for future reference, especially if they are part of a high-risk group or plan to travel to areas where meningococcal disease is prevalent.

Short Descr	MENACWY-TT MENB-FHBP VACC IM
Medium Descr	MENIGCCAL PNTVLNT MENACWY TT MENB FHBP VACC IM
Long Descr	Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y- tetanus toxoid carrier, and Men B-FHbp, for intramuscular use
Status Code	Non-Covered Service
Global Days	XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC)	9 - Not Applicable
Multiple Procedures (51)	9 - Concept does not apply.
Bilateral Surgery (50)	9 - Concept does not apply.
Physician Supervisions	09 - Concept does not apply.
Assistant Surgeon (80, 82)	9 - Concept does not apply.
Co-Surgeons (62)	9 - Concept does not apply.
Team Surgery (66)	9 - Concept does not apply.
Diagnostic Imaging Family	99 - Concept Does Not Apply
APC Status Indicator	Items and Services Not Billable to the MAC
Type of Service (TOS)	1 - Medical Care
Berenson-Eggers TOS (BETOS)	none
MUE	1